Coherus BioSciences Inc $ 15.43 -0.3 (-1.91%)
Warning! GuruFocus has detected 2 Severe warning signs with CHRS. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for CHRS (Coherus BioSciences Inc) from 2014 to Mar 03 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Coherus BioSciences stock (CHRS) PE ratio as of Mar 03 2021 is 9.46. More Details
Coherus BioSciences PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Coherus BioSciences PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:BEAM NAS:PHAT NAS:RVNC NAS:CYTK NAS:KNSA NAS:TBIO NAS:IMAB NAS:MGNX NAS:NSTG NAS:VCYT OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Traded in other countries CHRS.USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.